For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Other analysts are more cautious, however, predicting peaks sales of $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin ...

A 2021 study, for instance, estimated that obesity in the U.S. was associated ... “Improving access to new weight loss medications, along with existing evidence-based behavior change and weight ...

Earlier this fall, the Centers for Disease Control and Prevention reported data showing that adult obesity rates ... wait to understand how this new class of drugs affects weight loss at the ...

(Those are slightly higher shares than the estimate from the Center s for Disease Control and Prevention, which says around 40% of U.S. adults had obesity from 2021 ... the new drugs' true impact.

Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the South, where they had the highest dispensing rate of weight loss drugs ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

in New York City. Gary Hershorn/Getty Images Last year, poison control centers across the country reported spikes in calls related to overdoses of anti-obesity medications. Authorities attributed ...

U.S. obesity declined slightly in 2023, new data showed, perhaps marking the first time in over a decade there’s been a decline. The dip comes amid the booming popularity of weight loss drugs ...